What Is Emkay Investment Managers’ Outlook On Indian Markets?
Emkay Investment Managers Ltd. (EIML), a subsidiary of Emkay Global Financial Services, is a professional investment management company that provides portfolio management and advisory solutions to institutional and retail clients. With a focus on research-backed strategies and sector allocation, Emkay is known for its insights into equity markets, valuations, and earnings outlook. In its latest commentary, the firm outlined expectations for the upcoming quarters, touching upon rate cuts, sectoral strengths, and potential challenges in the market.
Further Rate Cuts Cannot Be Ruled Out
Emkay highlighted that monetary policy remains a critical driver for equity markets. With inflation cooling off and global central banks leaning toward accommodative stances, further rate cuts in India cannot be ruled out. A supportive interest rate environment would benefit borrowers, spur consumption, and improve valuations for rate-sensitive sectors such as banking, autos, and real estate.
Q2 Earnings Likely To Mirror Q1 Trends
According to Emkay, the second quarter of FY26 is unlikely to show significant deviation from the first quarter’s earnings performance. While certain pockets like capital goods, IT, and pharma are expected to remain strong, overall earnings momentum may remain steady rather than accelerating sharply. Companies with high operational efficiency and strong pricing power could continue to surprise positively.
H2FY26 Earnings Growth Expected At 12-13%
Emkay projects that the second half of FY26 will be stronger, with earnings growth in the range of 12–13%. The pickup is expected to be driven by improved consumption demand, margin recovery in manufacturing, and positive operating leverage in cyclical sectors. This guidance suggests that investors may need to be patient through the next few months before significant upside plays out.
IT Sector Attractive From Valuation Perspective
The IT sector, after facing headwinds from global slowdown fears and muted deal wins, has seen valuations correct meaningfully. Emkay believes that the sector now offers an attractive entry point, particularly for long-term investors. With cost optimization, AI-driven transformation, and large contract renewals on the horizon, IT companies may surprise on earnings resilience.
Pharma & CDMO: Structural Growth Stories
Pharmaceutical companies and Contract Development & Manufacturing Organisations (CDMOs) remain on Emkay’s positive radar. The firm expects strong demand in global generics, specialty products, and outsourcing services. India’s competitive cost structure and compliance record position domestic CDMOs favorably against international peers. The sector’s stable demand profile also makes it a defensive bet in volatile times.
Capital Goods: Earnings Good, Valuation A Concern
Capital goods companies are expected to deliver a healthy Q2 performance, backed by strong order inflows and government spending on infrastructure. However, Emkay cautions that valuations in this space are elevated. While earnings growth remains strong, investors must weigh the potential for limited upside given the high multiples at which many capital goods stocks are currently trading.
For traders looking for opportunities beyond sectoral insights, keeping track of index trends can be equally important. Here’s where you can find actionable short-term strategies: 👉 Nifty Tip | BankNifty Tip
Consumption: The Missing Link For Earnings Expansion
While cyclical recovery and export-oriented sectors are expected to contribute, Emkay notes that sustainable earnings growth in India requires a revival in consumption. Discretionary spending on lifestyle goods and steady demand for staples must accelerate for broader market earnings to reach projected levels. Without stronger household demand, earnings expansion may remain uneven.
Investor Takeaway
Emkay Investment Managers’ outlook reflects cautious optimism. While the first half of FY26 may remain stable, the second half is projected to deliver double-digit earnings growth. IT and pharma look promising, while capital goods face valuation concerns. Rate cuts, if they materialize, could further support sentiment. For investors, this is a period to stay selective, focus on quality names, and prepare for opportunities that may emerge in H2FY26.
📌 Stay updated with in-depth market insights and analysis by reading free content at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
